Octave vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health care clinic network with in-network insurance coverage, San Francisco CA, raised $52M+. Hybrid virtual and in-person therapy with major payer contracts.
About
Octave is a San Francisco, California-based mental health company founded in 2018 that operates a network of mental health clinics offering therapy and psychiatric care with in-network insurance coverage from major carriers. The company has raised over $52 million and has built a hybrid model offering both in-person care at physical clinic locations and virtual therapy, enabling clients to choose the modality that works best for their needs and circumstances.\n\nOctave's business model prioritizes in-network insurance access, negotiating directly with major commercial payers including Blue Cross Blue Shield, Aetna, and Cigna to make therapy financially accessible to patients who have historically faced high out-of-pocket costs or been directed to out-of-network providers. The company handles credentialing, insurance billing, and administrative infrastructure centrally, allowing its therapists and psychiatrists to focus on clinical work rather than paperwork.\n\nThe company has expanded to multiple markets in California and New York, with plans to grow its geographic footprint. Octave serves adults with a range of mental health conditions including anxiety, depression, relationship difficulties, trauma, and life transitions. By offering in-person clinic access alongside telehealth, Octave differentiates from purely virtual mental health platforms and appeals to clients who prefer or require face-to-face care. Octave is part of the emerging category of tech-enabled mental health clinic operators alongside Mindpath Health and Two Chairs.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.